{"groups":[{"description":"Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nMetformin Hydrochloride: Given orally","id":"FG000","title":"Arm I (EBRT, Metformin Hydrochloride)"},{"description":"Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nPlacebo: Given orally","id":"FG001","title":"Arm II (EBRT, Placebo)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}